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Stage III lung cancer remains a heterogeneous disease affect-
ing up to a third of newly diagnosed NSCLC patients annually.
Measurable successes have been made over the last decade,
but substantial room for improvement remains.
Combined cytotoxic chemotherapy and radiation ther-
apy is established as the standard treatment for patients
with medically inoperable or technically unresectable stages
II–III NSCLC. Multiple randomized studies and meta-analyses
demonstrate that concurrent radiochemotherapy results in
improved survival comparedwith sequential chemoradiother-
apy or RT alone.
Although numerous phase III trials have clearly demon-
strated a survival beneﬁt in those patients who receive
combined modality therapy, many questions remain. The
most effective combination of drugs, their optimal mode of
administration, the use of either induction or consolidation
therapy in addition to a backbone of concurrent therapy,
remain important issues to deﬁne. To date there have been
no conclusive clinical trials suggesting one radiochemother-
apy platform is superior to others. Neither there are no
convincing randomized phase III data to date supporting a
survival advantage for combining molecularly targeted agents
with chemoradiotherapy in the setting of locally advanced
NSCLC.
Combining chemotherapy and radiation therapy has still
not been able to overcome high rates of local failure, and toxi-
cities from these regimens remain an issue. Efforts to address
these concerns with regards to radiation therapy have focused
on improving tumor target deﬁnition, appropriately design-
ing treatment ﬁelds, and dose escalation. A recently presented
study demonstrates that radiotherapy dose escalation did not
improve chemoradiotherapy outcomes.
Finally investigations are ongoing regarding how to
optimally integrate modern radiotherapy techniques with
standard chemotherapy in patients with limited metastatic
disease.
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